Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

were
  • North America: 82.5% (85/103) for 900-mcg albinterferon alfa-2b, vs. 81.5% (88/108) for peginterferon alfa-2a;
  • Asia: 79.8% (75/94) for 900-mcg albinterferon alfa-2b, vs. 95.5% (85/89) for peginterferon alfa-2a;
  • Europe: 78.1% (64/82) for 900-mcg albinterferon alfa-2b, vs. 81.7% (67/82) for peginterferon alfa-2a;
  • Other regions: 75.8% (25/33) for 900-mcg albinterferon alfa-2b, vs. 74.2% (23/31) for peginterferon alfa-2a.
  • Patients receiving 900-mcg albinterferon alfa-2b had comparable rates of serious adverse events, severe adverse events, and discontinuations due to adverse events, vs. peginterferon alfa-2a.
  • The incidence of severe and/or serious adverse events was comparable between the two groups, with 17.3% (54/313) in the albinterferon alfa-2b 900-mcg treatment group, vs. 17.5% (54/309) in the peginterferon alfa-2a treatment group.
  • The incidence of severe and/or serious pulmonary adverse events was also comparable between these groups: severe and/or serious pulmonary infections were 0.6% (2/313) for 900-mcg albinterferon alfa-2b, vs. 0.6% (2/309) for peginterferon alfa-2a; and severe and/or serious respiratory, thoracic or mediastinal disorders were 1.0% (3/313) for 900-mcg albinterferon alfa-2b, vs. 1.3% (4/309) for peginterferon alfa-2a.
  • Overall, adverse events observed were those typically associated with interferon therapy, and the rate of discontinuations due to adverse events was comparable: 4.8% (15/313) for 900-mcg albinterferon alfa-2b, vs. 3.6% (11/309) for peginterferon alfa-2a.
  • Treatment Group Originally Randomized to Receive Albinterferon Alfa-2b 1200-mcg Every Two Weeks and Reduced to 900-mcg Following January 2008 Dose Modification, vs. Treatment Group Receiving Peginterferon Alfa-2a 180-mcg Every Week

    Due to the dose modification announced in J
    '/>"/>

    SOURCE Human Genome Sciences, Inc.
    Copyright©2008 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
    2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
    3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
    4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
    5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
    6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
    7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
    8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
    9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
    10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
    11. Premier Research Appoints Global Head of Human Resources
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
    (Date:7/23/2014)... 23, 2014 Shire plc ... global specialty biopharmaceutical company, and ArmaGen, a US ... licensing and collaboration agreement for AGT-182, an investigational ... of both the central nervous system (CNS) and ... II). This collaboration strengthens Shire,s rare disease pipeline ...
    (Date:7/23/2014)... 2014 China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... multi-product healthcare company catering to the mother and child segment, today ... across the PRC, Singapore , Hong ... , the Philippines and ...
    (Date:7/23/2014)... MD (PRWEB) July 23, 2014 a2z ... and ChirpE Mobile App, AACC Pathfinder, in its ... offerings. AACC’s annual meeting is planned for July 29-31, ... the place to be to connect with global leaders ... lab management, and other areas of breaking science in ...
    Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
    ... May 26, 2010 , , ... - Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction , ... Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( ... study to assess the safety and pharmacodynamics,of five oral insulin formulations in healthy subjects," ...
    ... 26 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, ... & Research Center at the University of Texas ... (CTRC) has started patient enrolment in a U.S. Phase ... combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic ...
    ... LONDON , May 26 ... announces the issuance of United States patent ... Treatment of Cancer and Other Neovascularization Disease, by the ... patent, which deepens the Company,s diverse portfolio of RNA ...
    Cached Biology Technology:Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 2Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 3Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial 4Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 2Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 3Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 4
    (Date:7/23/2014)... BOSTON , July 23, 2014 ... and threat detection, announced today it has been named ... . The Market Guide replaces Gartner,s well-known Magic Quadrant ... Gartner categorized BioCatch as one of several vendors to ... biometric analysis will become a standard feature of at ...
    (Date:7/23/2014)... -- The potential for clinical use of induced ... strategies has previously been hindered by the risk ... tumors. The ability to use etoposide treatment to ... of heart disease, specifically acute myocardial infarction, is ... and Development , a peer-reviewed journal from Mary ...
    (Date:7/23/2014)... Springer will publish the International Journal of Fuzzy ... the Taiwan Fuzzy Systems Association (TFSA). The cooperation will ... the area of fuzzy research., The International Journal ... papers that deal with the theory, design and application ... extension theory systems ranging from hardware to software. Launched ...
    Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
    ... think a city would provide a good home for bats ... buildings. But researchers at the University of Calgary made the ... for these animals. "I was really surprised," says Dr. ... biological sciences at the University of Calgary and lead author ...
    ... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
    ... State University shows that so-called biodegradable products are likely ... are releasing a powerful greenhouse gas as they break ... utensils, are broken down in landfills by microorganisms that ... a paper describing the research and professor and head ...
    Cached Biology News:Big city holds empty promise for bats 2Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2
    ... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
    Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
    ... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
    This modular laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Configurations are available with vertical or horizontal flow; options include a wo...
    Biology Products: